{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:28:04Z","timestamp":1737178084592,"version":"3.33.0"},"reference-count":53,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The inherited neuropathies are a clinically and genetically heterogeneous collection of neuropathies that neurologists, particularly neuromuscular specialists, must be familiar with. They include Charcot\u2013Marie\u2013Tooth disease, which is common yet currently lacks targeted treatment, and hATTRV polyneuropathy, which is rare but has disease-modifying gene therapies. With a focus on emerging new genes and treatments, this article offers a recent update on clinical diagnosis and management of inherited neuropathies.<\/jats:p>","DOI":"10.1055\/s-0044-1791520","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T23:43:47Z","timestamp":1729035827000},"page":"088-098","source":"Crossref","is-referenced-by-count":0,"title":["Top 10 Clinical Pearls in Inherited Neuropathies"],"prefix":"10.1055","volume":"45","author":[{"given":"Ruchee","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipasha","family":"Mukherjee-Clavin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1399-0004.1974.tb00638.x","article-title":"Genetic and clinical aspects of Charcot-Marie-Tooth's disease","volume":"6","author":"H Skre","year":"1974","journal-title":"Clin Genet"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41588-020-0615-4","article-title":"Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes","volume":"52","author":"A Cortese","year":"2020","journal-title":"Nat Genet"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Y Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"A Cortese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"D P Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"R J Desnick","year":"2003","journal-title":"Ann Intern Med"},{"volume-title":"Fabry disease: clinical features and diagnosis","author":"M Mauer","key":"ref7"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"S Waldek","year":"2009","journal-title":"Genet Med"},{"volume-title":"Fabry disease: treatment and prognosis","author":"M Mauer","key":"ref9"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1038\/s41598-021-86857-0","article-title":"Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients","volume":"11","author":"P La\u0161\u0161uthov\u00e1","year":"2021","journal-title":"Sci Rep"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jns.12485","article-title":"Long read sequencing overcomes challenges in the diagnosis of SORD neuropathy","volume":"27","author":"B R Grosz","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"100881","DOI":"10.1016\/j.gimo.2024.100881","article-title":"P004: urine polyols for diagnosis of sorbitol dehydrogenase (SORD) deficiency-related peripheral neuropathy*","volume":"2","author":"A White","year":"2024","journal-title":"Genet Med Open"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/ajmg.a.63383","article-title":"A medical odyssey of a 72-year-old man with Charcot-Marie-Tooth disease type 2 newly diagnosed with biallelic variants in SORD gene causing sorbitol dehydrogenase deficiency","volume":"191","author":"Y Furuta","year":"2023","journal-title":"Am J Med Genet A"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"e164954","DOI":"10.1172\/jci.insight.164954","article-title":"Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency","volume":"8","author":"Y Zhu","year":"2023","journal-title":"JCI Insight"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mus.23775","article-title":"Inherited neuropathies: clinical overview and update","volume":"48","author":"C J Klein","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich's ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","author":"A H Koeppen","year":"2011","journal-title":"J Neurol Sci"},{"volume-title":"Friedreich ataxia","author":"P Opal","key":"ref17"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S0735-1097(86)80159-0","article-title":"Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients","volume":"7","author":"J S Child","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0883073812448535","article-title":"Cardiomyopathy in Friedreich ataxia: clinical findings and research","volume":"27","author":"R M Payne","year":"2012","journal-title":"J Child Neurol"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"89","author":"D R Lynch","year":"2021","journal-title":"Ann Neurol"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich's ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"D R Lynch","year":"2023","journal-title":"Mov Disord"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/brain\/awx231","article-title":"Clinical, pathological and functional characterization of riboflavin-responsive neuropathy","volume":"140","author":"A Manole","year":"2017","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.parkreldis.2018.10.017","article-title":"Oral therapy for riboflavin transporter deficiency - what is the regimen of choice?","volume":"61","author":"S Gorcenco","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","article-title":"Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia","volume":"51","author":"A Cortese","year":"2019","journal-title":"Nat Genet"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1111\/ene.15310","article-title":"RFC1 repeat expansions: a recurrent cause of sensory and autonomic neuropathy with cough and ataxia","volume":"29","author":"D Beijer","year":"2022","journal-title":"Eur J Neurol"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/brain\/awaa015","article-title":"CANVAS with cerebellar\/sensory\/vestibular dysfunction from RFC1 intronic pentanucleotide expansion","volume":"143","author":"C Pais\u00e1n-Ruiz","year":"2020","journal-title":"Brain"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/brain\/awab150","article-title":"Removing the idiopathic from the chronic sensory neuropathies","volume":"144","author":"R C Roberts","year":"2021","journal-title":"Brain"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41582-019-0254-5","article-title":"Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges","volume":"15","author":"M Pipis","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/jnnp-2014-308826","article-title":"CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis","volume":"86","author":"V Fridman","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12035-012-8370-x","article-title":"The PMP22 gene and its related diseases","volume":"47","author":"J Li","year":"2013","journal-title":"Mol Neurobiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fneur.2020.00630","article-title":"Clinical and genetic diversity of PMP22 mutations in a large cohort of Chinese patients with Charcot-Marie-Tooth disease","volume":"11","author":"X Liu","year":"2020","journal-title":"Front Neurol"},{"issue":"15","key":"ref34","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1523\/JNEUROSCI.0325-09.2009","article-title":"Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects","volume":"29","author":"I Sargiannidou","year":"2009","journal-title":"J Neurosci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/brain\/awh048","article-title":"Phenotypic clustering in MPZ mutations","volume":"127","author":"M E Shy","year":"2004","journal-title":"Brain"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1093\/brain\/awaa323","article-title":"Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study","volume":"143","author":"M Pipis","year":"2020","journal-title":"Brain"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI124194","article-title":"Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model","volume":"129","author":"Y Zhou","year":"2019","journal-title":"J Clin Invest"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.gim.2021.08.009","article-title":"US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: a study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER)","volume":"24","author":"K A Phillips","year":"2022","journal-title":"Genet Med"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/1071100720922220","article-title":"A consensus statement on the surgical treatment of Charcot-Marie-Tooth disease","volume":"41","author":"G B Pfeffer","year":"2020","journal-title":"Foot Ankle Int"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"e220114","DOI":"10.1148\/rg.220114","article-title":"Charcot-Marie-Tooth disease of the foot and ankle: imaging features and pathophysiology","volume":"43","author":"L E Waldman","year":"2023","journal-title":"Radiographics"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/ptj\/59.6.766","article-title":"Standing wedge for increasing ankle dorsiflexion","volume":"59","author":"A A Guccione","year":"1979","journal-title":"Phys Ther"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jns.12548","article-title":"Effectiveness of exercise therapy for individuals diagnosed with Charcot-Marie-Tooth disease: a systematic review of randomized clinical trials","volume":"28","author":"R M Conde","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/jns.12116","article-title":"Systematic review of exercise for Charcot-Marie-Tooth disease","volume":"20","author":"A D Sman","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2352-4642(17)30013-5","article-title":"Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial","volume":"1","author":"J Burns","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/107110070102200308","article-title":"Biomechanical evaluation of the ability of casts and braces to immobilize the ankle and hindfoot","volume":"22","author":"S M Raikin","year":"2001","journal-title":"Foot Ankle Int"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4172\/2155-9562.1000465","article-title":"Hand rehabilitation treatment for Charcot-Marie-Tooth disease: an open label pilot study","volume":"09","author":"P Valeria","year":"2018","journal-title":"J Neurol Neurophysiol"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11832-012-0463-6","article-title":"Progression or not progression? How to deal with adolescent idiopathic scoliosis during puberty","volume":"7","author":"A Dimeglio","year":"2013","journal-title":"J Child Orthop"},{"issue":"07","key":"ref49","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2106\/00004623-200707000-00014","article-title":"Scoliosis in patients with Charcot-Marie-Tooth disease","volume":"89","author":"L A Karol","year":"2007","journal-title":"J Bone Joint Surg Am"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00381-020-04571-0","article-title":"Neurophysiologic intraoperative monitoring (NIOM) in pediatric patients with polyneuropathy","volume":"36","author":"J L McKinney","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"ref51","first-page":"7","article-title":"Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach","volume":"9","author":"D McCorquodale","year":"2016","journal-title":"J Multidiscip Healthc"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jns.12566","article-title":"Toxic medications in Charcot-Marie-Tooth patients: a systematic review","volume":"28","author":"G Cavaletti","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"930435","DOI":"10.3389\/fneur.2022.930435","article-title":"Accelerate clinical trials in Charcot-Marie-Tooth disease (ACT-CMT): a protocol to address clinical trial readiness in CMT1A","volume":"13","author":"K Eichinger","year":"2022","journal-title":"Front Neurol"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI96499","article-title":"PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models","volume":"128","author":"H T Zhao","year":"2018","journal-title":"J Clin Invest"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1172\/JCI98617","article-title":"Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A","volume":"128","author":"M E Shy","year":"2018","journal-title":"J Clin Invest"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/d41573-024-00020-8","article-title":"The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases","volume":"23","author":"P J Brooks","year":"2024","journal-title":"Nat Rev Drug Discov"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T23:31:28Z","timestamp":1737156688000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":53,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791520","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"type":"print","value":"0271-8235"},{"type":"electronic","value":"1098-9021"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}